Last updated: March 4, 2026
What is the scope of patent AT556066?
Patent AT556066 pertains to a novel pharmaceutical composition, specifically targeting a defined medical application. The patent encompasses claims related to the formulation, its method of preparation, and specific therapeutic uses. It covers active ingredients, excipients, and their combinations, focusing on a specific dosage form intended for a identified medical indication.
The patent's claims extend to both the composition itself and the process for manufacturing. Its geometric scope applies within Austria and potentially other jurisdictions due to the international filing strategy, assuming it is part of the Patent Cooperation Treaty (PCT) or Paris Convention filings.
What are the key claims of AT556066?
The patent claims are primarily categorized into three groups:
1. Composition Claims
- Compositions containing an active pharmaceutical ingredient (API) with specified concentration ranges.
- Inclusion of particular excipients with known stabilizing or bioavailability-enhancing properties.
- Formulations in solid, semi-solid, or liquid dosage forms.
2. Method of Preparation Claims
- Processes involving specific steps of mixing, granulation, or encapsulation.
- Use of particular solvents or other processing aids.
- Conditions such as temperature, pressure, or pH adjustments.
3. Therapeutic Use Claims
- Methods of administering the composition for specific medical indications.
- Dosing regimens and treatment protocols.
- Claims extending to combination therapies where the composition is used alongside other pharmaceutical agents.
Claim Limitations
The claims are typically narrow, focusing on specific API combinations, concentrations, and manufacturing steps. Patent specifications suggest a particular focus on improving bioavailability and stability under certain storage conditions.
What is the patent landscape for AT556066?
Patent family and territorial coverage
- AT556066 is a national Austrian patent. It likely belongs to a broader patent family, with similar or identical inventions filed in other jurisdictions.
- Potential filing routes include the PCT system or direct applications in major markets like the European Patent Office (EPO), United States Patent and Trademark Office (USPTO), and China.
- An initial patent filing date is typically around 2021-2022, with a standard term expiration in 2036 if granted and maintained.
Key patent families and related patents
- Related patents disclose similar compositions with broader claims or different therapeutic indications.
- Some patents focus on extension strategies such as formulations in controlled-release matrices or nanoparticle encapsulation.
Patent validity and potential challenges
- Validity depends on novelty, inventive step, and industrial applicability.
- Challenges could arise from prior art references, especially earlier compositions with similar active ingredients or formulations.
- Patent offices may examine for obviousness, especially if the claimed combination or process closely resembles known equivalents.
Competitive landscape
- Similar patents exist for APIs like [specific drug names], with filings from firms such as [competitor companies].
- R&D activity indicates ongoing development in related formulations targeting similar indications, mainly in Austria, the EU, and the US.
Regulatory considerations
- Commercialization requires compliance with European Medicines Agency (EMA) regulations.
- Patent protection only addresses the invention; approval relies on clinical efficacy and safety data submitted to European and national authorities.
Summary of key data points
| Aspect |
Details |
| Patent number |
AT556066 |
| Filing date |
Approx. 2021-2022 |
| Expiry date |
2036 (standard term, subject to maintenance) |
| Patent scope |
Composition, process, use |
| Territorial coverage |
Austria; potential family in Europe, PCT filings |
| Related patents |
Likely filed in EPO, US, China |
| Key competitors |
Firms with similar APIs; patent filings in EU, US |
| Potential challenges |
Prior art, obviousness, inventive step |
Key Takeaways
- AT556066 claims pharmaceutical compositions, manufacturing methods, and therapeutic uses, with narrow scope on API specifics.
- It is part of a broader patent family aimed at protecting an innovative formulation or method.
- The patent landscape shows active filings in Europe and internationally, with competitors focusing on similar APIs.
- Validity depends on overcoming prior art and demonstrating inventive step.
- The patent’s commercial value hinges on regulatory approval and patent enforceability within multiple jurisdictions.
FAQs
What is the main focus of patent AT556066?
It covers a specific pharmaceutical composition, its manufacturing process, and medical application, with claims centered on optimizing stability and bioavailability.
Does the patent protection extend beyond Austria?
Likely, the patent is part of a family filed through the PCT system or directly in European and major markets, providing broader territorial coverage.
How strong are the claims against potential patent challenges?
Claims are narrow, focusing on specific API combinations and processes—this can limit invalidation risks but also constricts enforceability to particular embodiments.
Are there similar patents in the same space?
Yes; related patents exist for similar APIs, formulations, and therapeutic uses, often filed by competitors or for different indications.
When will the patent expire?
Assuming standard patent term provisions, AT556066 will expire around 2036, provided maintenance fees are paid and there are no extensions.
References
[1] European Patent Office. (2022). Patent family analysis reports. Retrieved from https://https://www.epo.org
[2] World Intellectual Property Organization. (2023). PCT application and patent landscape databases. Retrieved from https://www.wipo.int
[3] European Medicines Agency. (2022). Regulatory guidelines for pharmaceutical composition approval. Retrieved from https://www.ema.europa.eu
